Skip to Main Content

Argenx, a Belgian drug maker, said Tuesday that its experimental medicine improved the symptoms of patients with a rare neuromuscular disease, achieving the primary goal of a late-stage clinical trial.

The positive study results will enable Argenx to seek U.S. approval before the end of the year as a potentially new treatment for patients with generalized myasthenia gravis, a chronic and debilitating condition in which the body’s own antibodies disrupt the communication between nerve endings and muscles.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!